Literature DB >> 16166193

Neonatal symptoms following maternal paroxetine treatment: serotonin toxicity or paroxetine discontinuation syndrome?

P M Haddad1, B R Pal, P Clarke, A Wieck, S Sridhiran.   

Abstract

We report a case of neonatal symptoms of irritability, increased tonus and convulsions after in-utero exposure to paroxetine 30 mg/day. The infant's symptoms commenced on the first day after birth and persisted for 10 days. Paroxetine levels were undetectable on day 6. Extensive investigations excluded infective and metabolic causes. Serotonin toxicity due to paroxetine seems the most likely mechanism, though an important differential diagnosis is a paroxetine discontinuation (withdrawal) syndrome. Differentiating between these two syndromes in the neonate presents a dilemma for clinicians. Irrespective of the mechanism, we recommend that all neonates exposed to antidepressants, particularly serotonin reuptake inhibitors (SSRIs), during the last trimester should be followed-up closely for adverse symptoms commencing in the first 10 days after birth. The possibility of such symptoms needs to be discussed with women who are considering starting or continuing antidepressant treatment in pregnancy. All neonatal adverse drug events should be reported to a pharmacovigilance centre. Further research is warranted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16166193     DOI: 10.1177/0269881105056554

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  10 in total

1.  Article is concerning.

Authors:  Dave Tomson; Rachel Burbeck; Stephen Pilling; Liz McDonald
Journal:  BMJ       Date:  2007-05-26

2.  Serotonin syndrome in a breast-fed neonate.

Authors:  Rachel Morris; Jean Matthes
Journal:  BMJ Case Rep       Date:  2015-05-06

Review 3.  Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects.

Authors:  Irma Convertino; Alice Capogrosso Sansone; Alessandra Marino; Maria T Galiulo; Stefania Mantarro; Luca Antonioli; Matteo Fornai; Corrado Blandizzi; Marco Tuccori
Journal:  Drug Saf       Date:  2016-10       Impact factor: 5.606

4.  Mother-infant antidepressant concentrations, maternal depression, and perinatal events.

Authors:  Dorothy Sit; James M Perel; Stephen R Wisniewski; Joseph C Helsel; James F Luther; Katherine L Wisner
Journal:  J Clin Psychiatry       Date:  2011-07       Impact factor: 4.384

Review 5.  Serotonin reuptake inhibitor-induced perinatal complications.

Authors:  Salvatore Gentile
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

Review 6.  Antidepressant use in pregnant and postpartum women.

Authors:  Kimberly A Yonkers; Katherine A Blackwell; Janis Glover; Ariadna Forray
Journal:  Annu Rev Clin Psychol       Date:  2013-12-02       Impact factor: 18.561

Review 7.  Perinatal depression: treatment options and dilemmas.

Authors:  Teri Pearlstein
Journal:  J Psychiatry Neurosci       Date:  2008-07       Impact factor: 6.186

Review 8.  A review of the management of antidepressant discontinuation symptoms.

Authors:  Emma Wilson; Malcolm Lader
Journal:  Ther Adv Psychopharmacol       Date:  2015-12

9.  Fluoxetine-induced perinatal morbidity in a sheep model.

Authors:  Rafael R Domingues; Adam D Beard; Meghan K Connelly; Milo C Wiltbank; Laura L Hernandez
Journal:  Front Med (Lausanne)       Date:  2022-08-04

10.  Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology.

Authors:  G M Goodwin; P M Haddad; I N Ferrier; J K Aronson; Trh Barnes; A Cipriani; D R Coghill; S Fazel; J R Geddes; H Grunze; E A Holmes; O Howes; S Hudson; N Hunt; I Jones; I C Macmillan; H McAllister-Williams; D R Miklowitz; R Morriss; M Munafò; C Paton; B J Saharkian; Kea Saunders; Jma Sinclair; D Taylor; E Vieta; A H Young
Journal:  J Psychopharmacol       Date:  2016-03-15       Impact factor: 4.153

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.